<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03718403</url>
  </required_header>
  <id_info>
    <org_study_id>Theophylline in PHP</org_study_id>
    <nct_id>NCT03718403</nct_id>
  </id_info>
  <brief_title>Effect of Theophylline in Pseudohypoparathyroidism</brief_title>
  <official_title>Effect of Theophylline in Pseudohypoparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the effect of theophylline in 40 subjects with Pseudohypoparathyroidism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is an open label intervention study for the off-label use of theophylline in
      psuedohypoparathyroidism (PHP).Theophylline is a is non-specific phosphodiesterase inhibitor
      which increases the levels of secondary messenger,cAMP. PHP patients have end organ
      resistance to hormones involving cAMP signaling. Thus, theophylline has a potential to
      abrogate hormone resistance. Also, it may have a role in bone maturation, neurocognition and
      metabolism.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 10, 2019</start_date>
  <completion_date type="Anticipated">April 10, 2032</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2030</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label intervention study, off label use of theophylline</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Theophylline on Bone Age in PHP</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change in Bone age ( in years and months) before and after theophylline administration for 52 weeks</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>PHP Ia</condition>
  <condition>PHP IB</condition>
  <condition>Php1C</condition>
  <arm_group>
    <arm_group_label>Single arm open labeled intervention study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with PHP will be given theophylline to decrease the end organ resistance by increasing levels of cAMP, a second messenger. Theophylline will be dosed twice a day for a period of 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophylline</intervention_name>
    <description>Theophylline will be given to maintain a peak level between 10-15 mcg/mL</description>
    <arm_group_label>Single arm open labeled intervention study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with known diagnosis of PHP1A and PHP1B

          -  Age &gt;5 years

        Exclusion Criteria:

          -  â€¢ Significant kidney disease, i.e. any CKD stage

               -  Hypercalciuria

               -  Kidney stones

               -  Severe Heart disease

               -  Uncontrolled seizure disorder

               -  Peptic ulcer

               -  Liver dysfunction

               -  Bleeding disorder

               -  Allergy to theophylline preparation

               -  Muscle disorder

               -  Infection

               -  Any neurologic disease

               -  Chronic drugs interacting with theophylline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AMITA SHARMA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AMITA SHARMA, MD</last_name>
    <phone>6177262908</phone>
    <email>asharma5@mgh.harvard.edu</email>
  </overall_contact>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 8, 2017</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>October 22, 2018</last_update_submitted>
  <last_update_submitted_qc>October 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Amita Sharma</investigator_full_name>
    <investigator_title>Medical Director, Division of Pediatric Nephrology</investigator_title>
  </responsible_party>
  <keyword>PHP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudohypoparathyroidism</mesh_term>
    <mesh_term>Pseudopseudohypoparathyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

